161,500 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Purchased by Quadrature Capital Ltd

Quadrature Capital Ltd bought a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 161,500 shares of the company’s stock, valued at approximately $2,704,000.

A number of other institutional investors have also recently made changes to their positions in TEVA. US Bancorp DE raised its holdings in shares of Teva Pharmaceutical Industries by 6.5% during the first quarter. US Bancorp DE now owns 10,812 shares of the company’s stock valued at $166,000 after purchasing an additional 656 shares during the last quarter. MAI Capital Management boosted its holdings in Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after purchasing an additional 697 shares during the last quarter. Wedbush Securities Inc. grew its position in Teva Pharmaceutical Industries by 3.3% in the 2nd quarter. Wedbush Securities Inc. now owns 21,995 shares of the company’s stock worth $369,000 after purchasing an additional 700 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Teva Pharmaceutical Industries by 15.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,474 shares of the company’s stock valued at $92,000 after buying an additional 715 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its holdings in shares of Teva Pharmaceutical Industries by 1.4% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 55,445 shares of the company’s stock valued at $929,000 after buying an additional 762 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $26.94 on Friday. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The business has a 50-day simple moving average of $21.60 and a two-hundred day simple moving average of $18.81. The stock has a market cap of $30.90 billion, a price-to-earnings ratio of -168.38, a PEG ratio of 1.11 and a beta of 0.70. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $26.96.

Insider Activity

In related news, Director Roberto Mignone sold 200,000 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total value of $4,822,000.00. Following the completion of the sale, the director directly owned 495,000 shares of the company’s stock, valued at approximately $11,934,450. This represents a 28.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.49% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on TEVA. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. UBS Group upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Finally, Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $25.86.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.